Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York NY 10021, USA.
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York NY 10021, USA.
Reprod Biomed Online. 2019 Oct;39(4):580-587. doi: 10.1016/j.rbmo.2019.06.005. Epub 2019 Jun 18.
Ooplasmic maturity has been studied for some time, but remains poorly defined. This study aimed to evaluate metaphase II (MII) oocyte competence in terms of fertilization, embryo development and cycle outcomes, according to the oocyte maturity ratio.
Couples treated by intracytoplasmic sperm injection (ICSI) between 1993 and 2017 with female partners ≤35 years old were included. Cycles were divided into four groups according to proportion of MII oocytes at the time of retrieval: optimal (76-100%), adequate (51-75%), partial (26-50%) and minimal (1-25%).
A total of 7672 ICSI cycles (optimal: 4838; adequate: 2252; partial: 518; minimal oocyte maturity: 64) were included, in which 95,667 MII oocytes were injected using ejaculated spermatozoa. The decreasing proportion of MII significantly reduced normal fertilization (two pronuclei) (78.9% to 71.3%; P < 0.0001) with a corresponding increase in digynic three-pronuclei that rose from 2.6% in the optimal group to 4.7% in the minimal group (P = 0.003). Implantation (33% to 17%; P < 0.0001), clinical pregnancy (63.6% to 37.5%; P < 0.0001) and live birth rates (49.2% to 26.6%; P < 0.0001) were affected by the decreasing proportion of MII oocytes.
A high proportion of immature sibling oocytes in the retrieved cohort affects the fertilization rate and embryo developmental competence of MII inseminated oocytes, clinical pregnancy and live birth rates, suggesting that, in addition to nuclear maturity, ooplasmic and membrane maturity are required for developmental competence of MII oocytes. These findings may provide guidance toward ovarian stimulation protocols aimed at achieving a greater proportion of MII oocytes, leading to higher fertilization rates and better pregnancy outcomes.
胞质成熟已经研究了一段时间,但仍然定义不明确。本研究旨在根据卵母细胞成熟率,评估中期 II (MII) 卵母细胞的受精、胚胎发育和周期结局。
纳入 1993 年至 2017 年间接受胞浆内单精子注射 (ICSI) 治疗且女性年龄≤35 岁的夫妇。根据取卵时 MII 卵母细胞的比例,将周期分为四组:最佳(76-100%)、充足(51-75%)、部分(26-50%)和最小(1-25%)。
共纳入 7672 例 ICSI 周期(最佳:4838 例;充足:2252 例;部分:518 例;最小卵母细胞成熟:64 例),其中使用射出精子注射了 95667 个 MII 卵母细胞。MII 卵母细胞比例的降低显著降低了正常受精(二原核)(78.9%至 71.3%;P<0.0001),同时双原核三原核的比例相应增加,从最佳组的 2.6%增加到最小组的 4.7%(P=0.003)。胚胎着床率(33%至 17%;P<0.0001)、临床妊娠率(63.6%至 37.5%;P<0.0001)和活产率(49.2%至 26.6%;P<0.0001)也受到 MII 卵母细胞比例降低的影响。
在采集的卵母细胞中,高比例的不成熟姐妹卵母细胞影响了 MII 授精卵的受精率和胚胎发育能力、临床妊娠率和活产率,提示除核成熟外,卵质和膜成熟对于 MII 卵母细胞的发育能力也是必需的。这些发现可能为卵巢刺激方案提供指导,旨在获得更高比例的 MII 卵母细胞,从而提高受精率和改善妊娠结局。